Efficacy of Baricitinib in Patients with Atopic Dermatitis and Atopic Comorbidities: Results of Pooled Data from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2)

被引：0
|
作者：
Wollenberg, Andreas [1 ]
Boguniewicz, Mark [2 ]
Travers, Jeffrey [3 ]
Thyssen, Jacob [4 ]
Goldblum, Orin [5 ]
Ball, Susan [5 ]
Sun, Luna [5 ]
Chen, Sherry [6 ]
Silverberg, Jonathan [7 ]
机构：
[1] Ludwig Maximillian Univ, Munich, Germany
[2] Natl Jewish Hlth, Denver, CO USA
[3] Wright State Univ, Dayton, OH 45435 USA
[4] Univ Copenhagen, Copenhagen, Denmark
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Syneos Hlth, Raleigh, NC USA
[7] Northwestern Univ, Feinberg Sch, Evanston, IL 60208 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
610
引用
收藏
页码：AB190 / AB190
页数：1
相关论文
共 50 条
  • [21] Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
    Wollenberg, A.
    Blauvelt, A.
    Guttman-Yassky, E.
    Worm, M.
    Lynde, C.
    Lacour, J. -P.
    Spelman, L.
    Katoh, N.
    Saeki, H.
    Poulin, Y.
    Lesiak, A.
    Kircik, L.
    Cho, S. H.
    Herranz, P.
    Cork, M. J.
    Peris, K.
    Steffensen, L. A.
    Bang, B.
    Kuznetsova, A.
    Jensen, T. N.
    osterdal, M. L.
    Simpson, E. L.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 437 - 449
  • [22] Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase III, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
    Blauvelt, A.
    Wollenberg, A.
    Pink, A.
    Peris, K.
    Armstrong, A.
    Spelman, L.
    Saeki, H.
    Lynde, C.
    Herranz, P.
    Barbarot, S.
    Simpson, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E110 - E111
  • [23] Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study
    Saeki, H.
    Kabashima, K.
    Tokura, Y.
    Murata, Y.
    Shiraishi, A.
    Tamamura, R.
    Randazzo, B.
    Imanaka, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (02) : 419 - 427
  • [24] Efficacy and safety of HAT1, a novel topical therapeutic: Results from randomized, double-blind, placebo-controlled clinical trials in psoriasis and atopic dermatitis
    Alex, Philip
    Sachdev, Mukta
    Centola, Casey
    Shilpakar, Rachana
    Williams, Sarah
    Ramnane, Mukesh
    Spergel, Jonathan
    Centola, Michael
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB120 - AB120
  • [25] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized Phase 3 clinical trials
    Hebert, Adelaide
    Flohr, Carsten
    Hong, H. Chih-ho
    Irvine, Alan
    Pierce, Evangeline
    Elmaraghy, Hany
    Xu, Wen
    Pillai, Sreekumar
    Dawson, Zach
    Siegfried, Elaine
    Weidinger, Stephan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB159 - AB159
  • [26] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
    Hebert, Adelaide A.
    Flohr, Carsten
    Hong, H. Chih-ho
    Irvine, Alan D.
    Pierce, Evangeline
    Elmaraghy, Hany
    Pillai, Sreekumar
    Dawson, Zach
    Chen, Sherry
    Armengol, Clara
    Siegfried, Elaine
    Weidinger, Stephan
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [27] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
    Hebert, Adelaide
    Flohr, Carsten
    Hong, H. Chih-ho
    Irvine, Alan
    Pierce, Evangeline
    Elmaraghy, Hany
    Xu, Wen
    Pillai, Sreekumar
    Dawson, Zach
    Siegfried, Elaine
    Weidinger, Stephan
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [28] Risk of anaphylaxis and conjunctivitis with tralokinumab in atopic dermatitis (AD): Analysis of a Phase 2b, randomized, double-blind, placebo-controlled study (NCT02347176)
    Wollenberg, A.
    Guttman-Yassky, E.
    Torpet, M.
    Silverberg, J. I.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 40 - 41
  • [29] Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Wallace, Daniel J.
    Furie, Richard
    Tanaka, Yoshiya
    Kalunian, Kenneth C.
    Mosca, Marta
    Petri, Michelle
    Dorner, Thomas
    Cardiel, Mario H.
    Bruce, Ian N.
    Gomez, Elisa
    DeLozier, Amy M.
    Janes, Jonathan
    Linnik, Matthew D.
    de Bono, Stephanie
    Silk, Maria E.
    Hoffman, Robert W.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [30] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
    Torrelo, A.
    Rewerska, B.
    Paller, Amy
    Prakash, A.
    Zhu, D.
    Pontes, M.
    Wu, Wen-Shuo
    Eichenfield, Lawrence F.
    Boecker, Ulrike
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
12345